These targets include NPM1 mutation, RUNX1-RUNX1T1 and CBF-MYH11 in CBF-AML, and PML-RARA in acute promyelocytic leukemia [4,36,45], for which real-time quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) methods have been standardized by the Europe Against Cancer (EAC) consortium [46] with a sensitivity threshold of 10−4 to 10−6. This evidence concerns the gene CEBPZ and acute myeloid leukemia.